SCHEMBL1665622

SCHEMBL1665622

CCCCCCCCCCCC=C=CCCCC(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 3/20 0.67
PPARG P37231 8/20 0.63
PPARD Q03181 7/20 0.63
PPARA Q07869 7/20 0.63
PTPN1 P18031 4/20 0.63
HSD17B10 Q99714 4/20 0.63
FABP4 P15090 4/20 0.63
TDP1 Q9NUW8 4/20 0.63
TERT O14746 3/20 0.63
MAPT P10636 3/20 0.63
BLM P54132 3/20 0.63
ALOX15 P16050 3/20 0.63
KMT2A Q03164 3/20 0.63
USP2 O75604 2/20 0.63
LMNA P02545 2/20 0.63
RECQL P46063 2/20 0.63
CYP19A1 P11511 2/20 0.63
NR4A2 P43354 2/20 0.63
GMNN O75496 1/20 0.63
CYP1A2 P05177 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27779756 0.96 PPARG (0.69) TOP1PPARGPPARDPPARAPTPN1
SCHEMBL28183464 0.96 PPARG (0.69) TOP1PPARGPPARDPPARAPTPN1
SCHEMBL8149939 0.96 PPARG (0.69) TOP1PPARGPPARDPPARAPTPN1
SCHEMBL9128942 0.96 PPARG (0.69) TOP1PPARGPPARDPPARAPTPN1
SCHEMBL3341235 0.96 PPARG (0.69) TOP1PPARGPPARDPPARAPTPN1
SCHEMBL29724318 0.96 PPARG (0.69) TOP1PPARGPPARDPPARAPTPN1
SCHEMBL11410056 0.92 F7 (0.69) TOP1PPARGPPARDPPARAPTPN1
SCHEMBL9632181 0.87 PPARG (0.78) TOP1PPARGPPARDPPARAPTPN1
SCHEMBL9632176 0.87 PPARG (0.78) TOP1PPARGPPARDPPARAPTPN1
SCHEMBL17540721 0.85 TERT (0.48) TOP1PPARGPPARDPPARAPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250354174-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS TIBA BIOTECH LLC (US) 2025-11-20 US claimed
US-12410448-B2 Nanoparticle compositions containing sugar functionalized nucleic acid carriers TIBA BIOTECH LLC (US) 2025-09-09 US claimed
EP-4387607-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS Tiba Biotech LLC (US) 2024-06-26 EP claimed
US-20240093238-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS TIBA BIOTECH LLC (US) 2024-03-21 US claimed
US-11859201-B2 Nanoparticle compositions containing sugar functionalized nucleic acid carriers TIBA BIOTECH LLC (US) 2024-01-02 US claimed
US-20230100837-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS TIBA BIOTECH LLC (US) 2023-03-30 US claimed
WO-2023022926-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS TIBA BIOTECH LLC (US) 2023-02-23 WO claimed
US-7485759-B2 Minimization of ligand degradation products, or reversion of same to useful phosphine ligands DOW TECHNOLOGY INVESTMENTS LLC (US) 2009-02-03 US claimed
US-20080114191-A1 MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OR REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS Union Carbide Chemicals & Plastics Technology LLC (formerly Union Carbide Chemicals & Plastics Techn (US) 2008-05-15 US claimed
CN-1997616-A Minimization of ligand degradation products, or conversion thereof to useful phosphine ligands UNION CARBIDE CHEM PLASTIC (US) 2007-07-11 CN claimed
US-20070100169-A1 Minimization of ligand degradation products, of reversion of same to useful phosphine ligands UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC 2007-05-03 US claimed
EP-1646599-A1 MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OR REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 2006-04-19 EP claimed
WO-2005007602-A1 MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OF REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 2005-01-27 WO claimed
US-20260078086-A1 VERSATILE BIODEGRADABLE MOLECULES AS NUCLEIC ACID CARRIERS TIBA BIOTECH LLC (US) 2026-03-19 US disclosed
US-20250354174-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS TIBA BIOTECH LLC (US) 2025-11-20 US disclosed
US-12410448-B2 Nanoparticle compositions containing sugar functionalized nucleic acid carriers TIBA BIOTECH LLC (US) 2025-09-09 US disclosed
CN-1997616-A Minimization of ligand degradation products, or conversion thereof to useful phosphine ligands UNION CARBIDE CHEM PLASTIC (US) 2007-07-11 CN disclosed
US-20070100169-A1 Minimization of ligand degradation products, of reversion of same to useful phosphine ligands UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC 2007-05-03 US disclosed
EP-1646599-A1 MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OR REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 2006-04-19 EP disclosed
WO-2005007602-A1 MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OF REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 2005-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250354174-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS TLR9, TLR3, TSG101 TOP1 855/4885PPARG 3751/4885PPARD 4307/4885
US-20230100837-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS TLR9, TLR3, TSG101 TOP1 855/4885PPARG 3751/4885PPARD 4307/4885
US-20080114191-A1 MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OR REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS PHOSPHO1, FFAR4, PTGER4 TOP1 3354/4885PPARG 79/4885PPARD 69/4885
US-20070100169-A1 Minimization of ligand degradation products, of reversion of same to useful phosphine ligands PHOSPHO1, FFAR4, NOTUM TOP1 3644/4885PPARG 91/4885PPARD 79/4885
US-20240093238-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS TLR9, TLR3, TSG101 TOP1 855/4885PPARG 3751/4885PPARD 4307/4885
US-12410448-B2 Nanoparticle compositions containing sugar functionalized nucleic acid carriers TLR9, TLR3, TSG101 TOP1 855/4885PPARG 3751/4885PPARD 4307/4885
US-11859201-B2 Nanoparticle compositions containing sugar functionalized nucleic acid carriers TLR9, TLR3, TSG101 TOP1 855/4885PPARG 3751/4885PPARD 4307/4885
US-20260078086-A1 VERSATILE BIODEGRADABLE MOLECULES AS NUCLEIC ACID CARRIERS NSUN2, SMC1A, SSU72 TOP1 61/4885PPARG 3970/4885PPARD 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.